dc.creatorAntas, P. R. Z.
dc.creatorCastello-Branco, L. R. R.
dc.date2019-04-02T14:45:52Z
dc.date2019-04-02T14:45:52Z
dc.date2008
dc.date.accessioned2023-09-27T00:14:31Z
dc.date.available2023-09-27T00:14:31Z
dc.identifierANTAS, P. R. Z.; CASTELLO-BRANCO, L. R. R. New vaccines against tuberculosis: lessons learned from BCG immunisation in Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene, v. 102, p. 628-630, 2008.
dc.identifier0035-9203
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/32329
dc.identifier10.1016/j.trstmh.2008.03.014
dc.identifier1878-3503
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8898867
dc.descriptionThe current tuberculosis (TB) vaccine Mycobacterium bovis BCG has been employed for some 70 years in Brazil and lessons from its use should be taken in account for the development or improvement of new TB vaccines. The vast majority of the current population has been vaccinated with BCG, with the possible requirement for a booster immunisation in adulthood for TB protection. BCG Moreau strain also protects against leprosy, meningitis and extrapulmonary forms of TB. Factors related to differences in strain, dosage and BCG administering protocol have been responsible for the variable efficacy of BCG. This vaccine is clearly affected by, as yet unclear, host and/or environmental variables. In this brief review, we describe some aspects of BCG immunisation observed in Brazil that may be of importance for improving or replacing BCG.
dc.description2022-01-01
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier
dc.rightsrestricted access
dc.subjectTuberculose
dc.subjectBCG
dc.subjectVacinas
dc.subjectImunização
dc.subjectRotas
dc.subjectTuberculosis
dc.subjectBCG
dc.subjectVaccines
dc.subjectImmunisation
dc.subjectRoutes
dc.subjectBrazil
dc.titleNew vaccines against tuberculosis: lessons learned from BCG immunisation in Brazil
dc.typeArticle


Este ítem pertenece a la siguiente institución